← Back to Search

Antiviral

ABBV-990 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 30 days

Summary

This trial tests ABBV-990, a new drug for COVID-19, on healthy adults to check its safety and how it moves through the body. Participants will take a pill and be monitored for side effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 30 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
AUC From Time 0 to Infinite Time (AUCinf) of ABBV-990
Apparent Terminal Phase Elimination Rate Constant (β) of ABBV-990
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-990
+4 more

Trial Design

5Treatment groups
Experimental Treatment
Group I: Group 5Experimental Treatment2 Interventions
Participants will receive ABBV-990 Dose E or matching placebo.
Group II: Group 4Experimental Treatment2 Interventions
Participants will receive ABBV-990 Dose D or matching placebo.
Group III: Group 3Experimental Treatment2 Interventions
Participants will receive ABBV-990 Dose C or matching placebo.
Group IV: Group 2Experimental Treatment2 Interventions
Participants will receive ABBV-990 Dose B or matching placebo.
Group V: Group 1Experimental Treatment2 Interventions
Participants will receive ABBV-990 Dose A or matching placebo.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AbbVieLead Sponsor
1,020 Previous Clinical Trials
520,067 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
442 Previous Clinical Trials
160,516 Total Patients Enrolled
~7 spots leftby Nov 2025